- XPhyto Therapeutics ( OTCQB:XPHYF ) has signed a non-binding Letter of Intent to identify and assess potential business synergies for manufacturing, import/export, distribution and product development with a US-based thin film manufacturing firm.
- The Firm operates a state-of-the art US-based FDA-certified pharma production facility managed by a seasoned leadership team with over 50 years of experience.
- The Firm is an ideal potential partner to produce XPhyto's oral dissolvable biosensor products.
- In addition, the Firm has a portfolio of OTC and FDA-approved products currently for sale in the US market.
For further details see:
XPhyto inks LOI for US manufacturing and strategic business opportunities